611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line

AzCH Nurse Assist Line


611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...

Medical Disorders
Basic InformationLookupsLatest News
Life in Space May Take Toll on Spinal MusclesHealth Tip: Understanding a Heart MurmurCalling All Blood Donors …Opioids Now More Deadly for Americans Than Traffic AccidentsWhy Your Heart Needs a Good Night's SleepNature or Nurture? Twins Study Helps Sort Out Genes' Role in DiseaseVaccines: Not Just for KidsExercise Caution to Protect Your Skin at the GymMake Cancer Prevention a Priority in 2019AHA: New Cholesterol Guidelines Put Ethnicity in the SpotlightBroad-Range Ebola Drug Shows Promise in Animal TestsPrescription Opioids May Raise Pneumonia RiskHealth Tip: Prevent Travelers' DiarrheaCancer Patients May Face Greater Risk of ShinglesThyroid Surgery Complications Can Land Some Back in the HospitalRadiation Doses From CT Scans Vary WidelyHealth Tip: Job-Related Chemical Exposure Through the SkinJob Insecurity May Take a Toll on Your HeartPhysical Therapy Can Keep Sports Injuries at BayPersistent Cough May Mean See Your Doctor1 in 10 Adults Have Food Allergies, But Twice as Many Think They DoCatching Up on News About Catch-Up SleepHepatitis C Screening Can Help Prevent Liver DiseaseCan Herbal Drug Kratom Kill?Cholesterol Levels Spike After ChristmasDeadly Meningitis B Targets College StudentsNew Cholesterol Drug's High Price May Not Be Worth It: StudyAsthma Often Goes Undetected in Urban Teens, Study FindsBe Alert for Concussions in Young AthletesHow Seniors Can Prevent Hypothermia This WinterWhopping Numbers on Whooping CoughKidney Disease Risk Tied to Sugar-Sweetened DrinksHealth Tip: Understanding Whooping CoughHealth Tip: Strep Isn't an Ordinary Sore ThroatHolidays' Pitfalls for Those With Food AllergiesWinter's Many Challenges to Eye HealthHeart Risks High in Older Cancer Patients Before DiagnosisCertain Antibiotics Tied to Deadly Heart Vessel Tears: FDAHepatitis C Cases Cluster in States Hit Hard by OpioidsEven Non-Concussion Head Hits Affect Young Football Players' VisionAverage American Getting Fatter, but Not Taller1 in 4 People Over 25 Will Be Hit by StrokeWearing Contacts 24/7 Can Bring Infection, Blindness, Doctors WarnFood Allergies Tied to MS RelapsesRunaway Immune System May Play Role in Chronic Fatigue SyndromeMigraine's 'Silver Lining': Lowered Risk for Diabetes?Health Tip: Use Medical Devices SafelyFast Facts for Men (and Women) About High CholesterolDon't Let Holiday Season Stress Worsen Your Allergies, AsthmaSave Your Skin From the Ravages of Cold Weather
Questions and AnswersLinksBook Reviews
Related Topics

Men's Health
Women's Health

3-Drug Therapy Might Be Cystic Fibrosis 'Breakthrough'

HealthDay News
by By Amy Norton
HealthDay Reporter
Updated: Oct 18th 2018

new article illustration

THURSDAY, Oct. 18, 2018 (HealthDay News) -- In what researchers are calling a "breakthrough," two preliminary trials have found that either of two triple-drug regimens could potentially benefit 90 percent of people with cystic fibrosis.

The trials were short-term, finding that the drug combinations improved adult patients' lung function over four weeks. But experts said they were optimistic the results will hold up in the larger, longer-term trials already underway.

What's most exciting, they said, is that the triple-drug approach could open up new options to nearly all cystic fibrosis patients.

"This is not a cure for cystic fibrosis," stressed Dr. Steven Rowe, who led one of the trials. "But it could be game-changing."

Cystic fibrosis (CF) is a genetic disorder that causes persistent lung infections. Over time, extensive lung damage leads to respiratory failure. At one time, children with CF usually died before they reached school age. But with improved treatments, the typical life expectancy is now about 40 years, according to the Cystic Fibrosis Foundation.

Cystic fibrosis is caused by various mutations in a gene called CFTR. In the past several years, drugs that target those underlying genetics have become available. Known as CFTR modulators, they were heralded as a major advance in treating the disorder.

However, they work well only for a small number of people with certain CFTR mutations, explained Rowe, director of the Cystic Fibrosis Research Center at the University of Alabama at Birmingham.

The most common mutation that causes cystic fibrosis is called F508del -- and it has proven tougher to tackle, Rowe said.

About half of people with CF carry two copies of the mutation (one inherited from each parent). For them, a combination of two existing CFTR modulators can ease breathing problems -- but the overall effects are only "modest," Rowe said.

Then there's the 30 percent of CF patients who carry only one copy of F508del, plus another defect known as a "minimal-function" mutation. For them, the existing CFTR modulators do not work at all.

Both new trials focused on those two groups of patients. The results are published in the Oct. 18 New England Journal of Medicine, to coincide with the researchers' presentation at a North American Cystic Fibrosis meeting, in Denver.

Rowe's team tested a combination of two available CFTR modulators -- tezakaftor and ivakaftor -- plus an experimental one, known as VX-659. The other trial used the same existing drugs, along with a similar new drug, dubbed VX-445.

Rowe's team randomly assigned 54 adults with cystic fibrosis to either take the triple-drug regimen or be in a comparison group. In the comparison group, patients with one F508del mutation took placebo pills, while patients with two copies of the mutation took tezakaftor and ivakaftor alone.

After four weeks, the trial found, the triple-drug therapy had improved lung function in patients with both types of mutations. Their performance on a test called FEV1 rose by as much as 13 percentage points, on average -- what Rowe described as a "pronounced improvement."

The other trial had nearly identical results.

This is the first time, Rowe said, that CFTR modulator therapy has "pushed the needle" for patients with one F508del mutation.

An editorial published with the studies said they "represent a major breakthrough."

Now the questions are whether the improved lung function can be sustained, and whether the drugs prevent symptom exacerbations and other complications, wrote Dr. Fernando Holguin, of the University of Colorado, Aurora.

The Cystic Fibrosis Foundation helped fund the work through a grant to Vertex Pharmaceuticals, Inc., which is developing both experimental drugs.

"The ability of these potential drugs to treat individuals with a single F508del mutation means that more people than ever before could benefit," said Dr. Michael Boyle, senior vice president for therapeutics at the foundation. "This is very exciting news for our community."

Rowe agreed there are still important questions about the triple-drug regimens. One is, how well do they work for younger patients?

Patients as young as 12 are included in the larger ongoing trials, Rowe said.

So far, the treatments appear safe. Most side effects in the four-week trials were "mild to moderate," the researchers said, and included cough, headache and increased sputum.

If the experimental drugs are ultimately approved, there will be the real-world issue of price.

Vertex currently markets the combination of tezakaftor and ivakaftor as Symdeko -- at a reported list price of $292,000 a year.

In the United States, more than 30,000 people have cystic fibrosis, according to the foundation.

More information

For an overview of cystic fibrosis, visit the Cystic Fibrosis Foundation.